TABLE 2.
Anti‐cancer drug preparations delivered in HAH during the two periods
| INN | Administration route | Number of preparations ‘period 1’ (%) | Number of preparations ‘period 2’ (%) | Evolution rate (%) |
|---|---|---|---|---|
| Arsenic Trioxide | IV | 28 (2.1) | 29 (1.7) | +3.6 |
| Azacitidine | SC | 874 (65.8) | 920 (54.9) | +5.3 |
| Bortezomib | SC | 237 (17.8) | 274 (16.3) | +15.6 |
| Carfilzomib | IV | 44 (3.3) | 105 (6.3) | +138.6 |
| Cytarabine | IV | 63 (4.7) | 113 (6.7) | +79.4 |
| Daratumumab | IV | 24 (1.8) | 36 (2.1) | +50 |
| Nivolumab | IV | 4 (0.3) | 9 (0.5) | +125 |
| Paclitaxel | IV | 2 (0.2) | 11 (0.7) | +450 |
| Rituximab | SC | 20 (1.5) | 11 (0.7) | −45 |
| Trastuzumab | SC | 7 (0.5) | 72 (4.3) | +928.6 |
| Vinorelbine | IV | 9 (0.7) | 15 (0.9) | +66.7 |
| Others | SC or IV | 17 (1.3) | 81 (4.8) | +376.5 |
| TOTAL | 1329 (100) | 1676 (100) | +26.1 |
INN, International Non‐proprietary Name; IV, intravenous; SC, subcutaneous; Others, Belinostat, Bendamustine, Bevacizumab, Bleomycin, Brentuximab Vedotin, SC Cytarabine SC, Dacarbazine, Doxorubicin, Durvalumab, Eribulin, Fluorouracile, Gemcitabine, Irinotecan, Pembrolizumab, Pertuzumab, IV Rituximab, Trastuzumab Emtansine, Vinblastine, Vincristine, Vindesine
*
Chi‐squared test p < .01.